THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND Patent applications |
Patent application number | Title | Published |
20160129110 | IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS - Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab) | 05-12-2016 |
20150209487 | DRUG DELIVERY DEVICES AND METHODS OF MAKING AND USING SAME - The disclosure provides drug delivery devices and methods of making and using the drug delivery devices. The devices include single and multi-layer polymer films made by a breath figure technique having therapeutic agents associated therewith. For example, the devices may be a dual layer polymer film wherein the first layer includes a therapeutic agent incorporated into it by spin coating the first agent with a polymer solution and the second agent is incorporated into the second layer by loading the agent into pores of the second layer after it is spin coated onto the first layer. In some cases one layer provides a burst release and the second layer provides a slow release drug delivery profile. The devices may take on the form of a surgical mesh with a slow release therapeutic drug. | 07-30-2015 |
20150153367 | CAPILLARY NETWORK DEVICES AND METHODS OF USE - Artificial microvascular network (AMVN) devices are provided and related methods of making and methods of using such devices are provided. The present disclosure generally relates to an AMVN device comprising a substrate including a capillary network configured so as to simulate those actually encountered in the circulation of various humans and animal model systems. In certain aspects, the AMVN devices may be used, e.g., to investigate the effect of storing RBCs under aerobic and anaerobic conditions. However, the use of such AMVN devices is not so limited. | 06-04-2015 |
20150119318 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING HERPESVIRUS INFECTION - The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject. | 04-30-2015 |
20150112244 | SELECTIVELY POLYMERIZABLE COMPOSITIONS AND METHODS OF USE IN VIVO - Otologic materials and methods are provided. For example, a cell-adhesive, biodegradable hydrogel scaffold loaded with time-released drugs for repairing chronic tympanic membrane perforations is disclosed, methods of making same and administering same are provided. This hydrogel may promote vascular in-growth and epithelial cell growth of the tympanic membrane with the purpose of closing the perforation and providing a barrier between the external and middle ear. The hydrogel is initially a liquid polymer that only gels upon exposure to specific conditions, such as exposure to light. This scaffold may simultaneously induce repair of the tympanic membrane while preventing or alleviating middle ear infection, thus filling a void in current tympanic membrane perforation therapies. | 04-23-2015 |
20150087693 | MICRO-RNAS INVOLVED IN MACULAR DEGENERATION - The present invention relates to the involvement of miR function in the development of age-related macular degeneration (AMD). It is shown that miR-23, miR-24 and/or miR-27 are involved in pathologic neovascularization in AMD, and that agonism (miR-24) and inhibition (miR23/27) of the function of these molecules blocks events contributing to development and progression of disease. | 03-26-2015 |
20150056710 | CHARACTERIZATION OF POLYMER AND COLLOID SOLUTIONS - Simultaneous Multiple Sample Light Scattering systems and methods can be used to for polymer stability testing and for applying stressors to polymer or colloid solutions including heat stress, ultrasound, freeze/thaw cycles, shear stress and exposure to different substances and surfaces. among others, that create a polymer stress response used to characterize the polymer solution and stability. | 02-26-2015 |
20140377740 | SOLUBLE AND MEMBRANE-ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS - Soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins are disclosed, as well as diagnostic and preventative methods using these compositions. Also disclosed are methods including preparation of vaccines, factors (e.g. small molecules) that inhibit LASV infectivity, and diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses. | 12-25-2014 |
20140295472 | Paper Based Diagnostic Test - A device utilizing agglutination and its method of use to diagnose diseases or conditions. The diagnostic device may comprise a substrate having pores, an agglutination zone, and a test readout zone wherein said agglutination zone is functionalized with an agglutinating agent to cause agglutination of the sample. | 10-02-2014 |
20140271650 | IMMUNOGENIC PEPTIDE CONJUGATE AND METHOD FOR INDUCING AN ANTI-INFLUENZA THERAPEUTIC ANTIBODY RESPONSE THEREWITH - Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections. | 09-18-2014 |
20140271580 | IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS - Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab) | 09-18-2014 |
20140243256 | ARENAVIRUS INHIBITING PEPTIDES AND USES THEREFOR - The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15). | 08-28-2014 |
20140236170 | MULTI-COMPONENT DETACHABLE JAW TOOLS AND METHODS OF USING AND MAKING SAME - Provided is a jaw tool formed from two separable units and which includes a fastening device that attaches the two units together when the jaw tool is in use and which may automatically separate the units after the device performs its function such as clamping and/or cutting. Also provided is a jaw tool having a cutting blade wherein the contours of the device are shaped so that force is concentrated on the cutting bade when the device is closed. The jaw tool may be manufactured from a single injection molded-component that is used in duplicate to form the jaw tool. The jaw tool may be used in various applications in which it may be beneficial to simultaneously clamp and cut an object, such as various medical applications including vascular, gastrointestinal, respiratory, and placental. | 08-21-2014 |
20140206912 | UNDERGROUND REACTOR SYSTEM - An underground reactor for creating hydrocarbons and chemicals from organic material preferably includes a heat recovery device. Some embodiments of the present invention include at least one tube that injects biomass underground and at least one second tube that collects reacted biomass on the surface. Further tubes are also disclosed for the ability to control temperature and pressure and collect minerals and carbon dioxide. Methods for utilizing the reactor are additionally provided. Further embodiments include methods of using the reactor such as, for example, methods of creating fuel from algae and methods of using the minerals and carbon dioxide as food for an algae farm that will be used as biomass for the reactor. | 07-24-2014 |
20140194347 | INFLUENZA INHIBITING COMPOSITIONS AND METHODS - The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR. | 07-10-2014 |
20140178422 | PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM - Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described. | 06-26-2014 |
20140166575 | OIL EMULSIFICATION AND POLYCYCLIC AROMATIC HYDROCARBON ADSORPTION USING FINE PARTICLES AS DISPERSANTS - A method for cleaning an oil spill in a marine environment includes forming a particle-stabilized emulsion containing seawater, carbon black and at least one oil spill component and allowing the at least one oil spill component to degrade, thereby removing said component from the marine environment. Carbon black can be added to an oil-seawater mixture to form a stabilized emulsion containing at least one oil spill component and the oil spill component allowed to degrade, thereby removing the at least one oil spill component from the oil spill. Also disclosed is an emulsion that includes one or more oil spill components, seawater and carbon black particles. | 06-19-2014 |
20140080115 | DEVICE AND METHOD FOR MONITORING THE PRESENCE, ONSET AND EVOLUTION OF PARTICULATES IN CHEMICALLY OR PHYSICALLY REACTING SYSTEMS - A device for monitoring particulates includes a means for correlating measurements of pressure across at least one filter, flow rate of a sample through the filter, or a combination thereof to the properties of particulates in a solution. More particularly, the device can be used for monitoring particulates in a reacting system to provide signals to the user or control input to the reacting system to alter the course of the reaction according to a desired path. | 03-20-2014 |
20140046105 | UNDERGROUND REACTOR SYSTEM - An underground reactor for creating hydrocarbons and chemicals from organic material can include a heat recovery device. Some embodiments of the present disclosure include at least one tube that injects biomass underground and at least one second tube that collects reacted biomass on the surface. Further tubes are also disclosed for the ability to control temperature and pressure and collect minerals and carbon dioxide. In another embodiment, a super-critical fluid is injected into the underground reactor. Methods for utilizing the reactor are additionally provided. Further embodiments include methods of using the reactor such as, for example, methods of creating fuel from algae and methods of using the minerals and carbon dioxide as food for an algae farm that will be used as biomass for the reactor. | 02-13-2014 |
20140045752 | MULTICOMPONENT COMPOSITIONS AND THE USES - Multicomponent compositions and methods of use thereof are disclosed herein. Some embodiments of the present invention include multicomponent compositions comprising a first component and a second component, where the first component comprises a notch influencing molecule and the second component comprises a GPCR targeted molecule. Kits comprising the multicomponent composition are also disclosed. Methods for providing the multicomponent composition to one or more cells are additionally provided. Further embodiments include methods of using the multicomponent composition such as, for example, methods of administering the multicomponent composition and method of treating organisms (such as mammals) using the multicomponent composition. | 02-13-2014 |
20140045743 | COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION - The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof. | 02-13-2014 |
20140017298 | BIOPOLYMER HOOKS TO CREATE COATINGS ON LIPOSOMES - The disclosed invention involves creating coatings on liposomes to increase stability within the body for drug delivery. The present invention includes a composition used for drug delivery, comprising liposomes and hydrophobically modified polysaccharides with alkyl groups, wherein the alkyl groups physically attach to and coat the liposomes. | 01-16-2014 |
20140004178 | OMV VACCINE AGAINST BURKHOLDERIA INFECTIONS | 01-02-2014 |
20130273570 | METHOD FOR IDENTIFICATION AND CULTURE OF MULTIPOTENT MESENCHYMAL STEM CELLS WITH HIGH PROLIFERATION POTENTIAL - Variations in the differentiation and lineage potential of stem cells, including mesenchymal stem cells, currently limit their therapeutic use. The ability to identify, isolate, and specifically amplify stem cell populations with desired differentiation potential would contribute the use of stem cells in research and therapy. The present invention discloses a method of assessing differentiation potential of stem cells by measuring the differential expression of antigens CD146 and NG2 on the stem cells. The con elation between CD146 and NG2 expression and differentiation and trilineage potential is explored. The invention also discloses methods to specifically amplify or enrich stem cells with desired differentiation potential, monitor the differentiation potential of a heterogeneous stem cell population, quantify the heterogeneity in differentiation potential of a stem cell culture, and remove stem cells with specific differentiation potentials from a heterogeneous cell culture. | 10-17-2013 |
20130184475 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER - Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth. | 07-18-2013 |
20130172242 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders. | 07-04-2013 |
20130143288 | ISOLATED BACTERIA, METHODS FOR USE, AND METHODS FOR ISOLATION - Isolated bacteria are disclosed. The isolated bacteria are aerotolerant and can produced butanol. Methods are disclosed to produce generated chemicals. Methods are disclosed to isolate aerotolerant bacteria. | 06-06-2013 |
20130115699 | POLYPLEX GENE DELIVERY VECTORS - Compositions comprising linear PNAI, cyclic PNAI, linear PEI, and/or cyclic PEI, useful for delivering compounds or substances into a cell, are provided, as well as methods of making linear PNAI, cyclic PNAI, linear PEI, and cyclic PEI. Also provided are methods of using compositions comprising linear PNAI, cyclic PNAI, linear PEI, and/or cyclic PEI for introducing substances into a cell. | 05-09-2013 |
20130065816 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE - This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents. | 03-14-2013 |
20130058724 | NOVEL MULTIFUNCTIONAL MATERIALS FOR IN-SITU ENVIRONMENTAL REMEDIATION OF CHLORINATED HYDROCARBONS - Effective in-situ injection technology for the remediation of dense nonaqueous phase liquids (DNAPLs) such as trichloroethylene (TCE) benefits from the use of decontamination agents that effectively migrate through the soil media, and react efficiently with both dissolved TCE and bulk TCE. A novel decontamination system contains highly uniform carbon microspheres preferably in the optimal size range for transport through the soil. The microspheres are preferably enveloped in a polyelectrolyte (such as carboxymethyl cellulose, CMC) to which preferably a bimetallic nanoparticle system of zerovalent iron and Pd is attached. The carbon serves as a strong adsorbent to TCE, while the bimetallic nanoparticles system provides the reactivity. The polyelectrolyte serves to stabilize the carbon microspheres in aqueous solution. The overall system resembles a colloidal micelle with a hydrophilic shell (the polyelectrolyte coating) and a hard hydrophobic core (carbon). In contact with bulk TCE, there is a sharp partitioning of the system to the TCE side of the interface due to the hydrophobicity of the core. These multifunctional systems appear to satisfy criteria related to remediation and are relatively inexpensive and made with potentially environmentally benign materials. An aerosol process is preferably used to produce zerovalent iron particles supported on carbon. A method of lubricating includes creating carbon microspheres produced from a monosaccharide or polysaccharide, the carbon microspheres having a diameter of 50 nm to 6 microns, coating the microspheres with a surface coating and using the carbon microspheres as a lubricant. | 03-07-2013 |
20130041022 | Glyceollins Suppress Androgen-Responsive Prostate Cancer - The present disclosure demonstrates the molecular effects of glyceollins on human prostate cancer cell LNCaP to further elucidate its potential effects on prostate cancer prevention. The glyceollins inhibited LNCaP cell growth similar to that of the soy isoflavone genistein. The growth inhibitory effects of the glyceollins appeared to be due to an inhibition on G1/S progression and correlated with an up-regulation of cyclin-dependent kinase inhibitor A1 and B1 mRNA and protein levels. By contrast, genistein only up-regulates cyclin-dependent kinase inhibitor A1. In addition, glyceollin treatments led to down-regulated mRNA levels for androgen responsive genes. In contrast to genistein, this effect of glyceollins on androgen responsive genes appeared to be mediated through modulation of an estrogen- but not androgen-mediated pathway. Hence, the glyceollins exerted multiple effects on LNCaP cells that may be considered cancer preventive and the mechanisms of action appeared to be different from other soy-derived phytochemicals. | 02-14-2013 |
20130005648 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING HERPESVIRUS INFECTION - The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject. | 01-03-2013 |
20120309683 | USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES - This invention relates to methods and compositions for the treatment, management, reduction, or prevention of injuries to one or more major organs of the body, e.g., the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of a mammal (e.g., a human) caused by one or more calcineurin or mammalian target of rapamycin (mTOR) complex inhibitors. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds to the mammal. Combination therapy with one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents, plus one or more inhibitors of either calcineurin or the mTOR complexes can be used to treat organ transplantation, autoimmune diseases, graft-versus-host disease, Behçet's disease, hematological cancers, noninfectious uveitis, sarcoidosis, tuberous sclerosis complex, acute neurological diseases, age-related neurodegenerative diseases, Huntington's disease and other CAG codon repeat expansion diseases, keratoconjunctivitis sicca, and restenosis. | 12-06-2012 |
20120308642 | INHIBITING HEPATITIS C VIRAL REPLICATION WITH SIRNA COMBINATIONS - Compositions are disclosed of combinations of small interfering RNAs (siRNA) that can inhibit the replication of hepatitis C virus (HCV) in liver cells, along with methods of co-administering the siRNAs to subjects. Further, methods are disclosed for improving the delivery of nucleic acids to the liver. | 12-06-2012 |
20120289458 | TREATMENT OF INFLUENZA VIRUS INFECTION - The present invention provides method for the treatment of an ongoing influenza infection by administering a polypeptide to a subject suffering from an influenza infection. The polypeptide consists of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or an 8 to 40 amino acid residue portion thereof. In one embodiment, the polypeptide consists of SEQ ID NO: 4 or an 8 to 40 contiguous amino acid residue portion thereof. The present invention also provides a method of interfering with fusion of an influenza virus envelope with a host cell membrane by contacting the host cell with the FIR polypeptide. | 11-15-2012 |
20120233079 | Copyright Status Determination System and Method - A system and method for determining the copyright status of a work is provided, comprising presenting one or more initial questions about a work, wherein the initial questions are selected from a question set stored in a first database; receiving an initial response to the initial questions; presenting a subsequent question about the work from the question set, wherein the subsequent question is selected based on the initial responses and a rule set stored in a second database, and wherein the rule set contains rules related to copyright law; receiving a subsequent response to each of the subsequent questions in accordance with the rule set until the copyright status is determined; and displaying the copyright status. | 09-13-2012 |
20120219576 | LASSA VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF - The instant invention is directed to novel Lassa virus-like particle (VLP) compositions and methods of production thereof. The inventive VLPs comprise, for example, the Lassa virus (LASV) Z matrix protein, glycoproteins (GPs)-I and -2, and nucleoprotein (NP). A novel method for producing these VLPs comprises constructing multicistronic plasmids for the expression of VLP protein components from a single vector. One example is a tricistronic vector containing DNA sequences encoding the LASV Z, GPC and NP proteins. The VLPs provided by the present invention can be used for research, therapeutic and diagnostic purposes. | 08-30-2012 |
20120190630 | AMINO ACID-BASED COMPOUNDS, THEIR METHODS OF USE, AND METHODS OF SCREENING - Described herein are compounds that comprise amino acids and their pharmaceutical compositions. Methods used to administer the compounds are described. Screening methods including those for determining | 07-26-2012 |
20120135918 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF - The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A | 05-31-2012 |
20110290998 | TUNED SYNTHETIC DENDRIMER CALIBRANTS FOR MASS SPECTROMETRY - Provided are monodisperse synthetic dendrimer calibrants for mass spectrometry. The calibrants are distinguished by their relative ease and rapidity of synthesis, comparatively low cost, long shelf life, high purity, and amenability to batch synthesis as mixtures. The latter characteristic enables parallel preparation of higher molecular weight compounds displaying useful distributions of discrete molecular weights, thereby providing multi-point mass spectrometry calibration standards. Methods of making and using said calibrants are also provided. | 12-01-2011 |
20110237505 | Compositions and Methods for Treating Obesity and Diabetes - Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal. | 09-29-2011 |
20110190483 | Stimulus-Responsive Apta Chelamers - Disclosed are apta-chelamers comprising aptamer domains tethered to rationally designed synthetic protein-binding modules, and methods of designing and making the same. Also disclosed are stimulus-responsive apta-chelamers capable of simultaneously or sequentially binding (and, thus, inhibiting) two protein targets. | 08-04-2011 |
20110130328 | FLAVIVIRUS FUSION INHIBITORS - The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided. | 06-02-2011 |
20100137877 | Combined Umbilical Cord Cutter, Clamp, and Disinfectant - Provided is a combined umbilical cord clamp, cutter, disinfectant, and data collecting system which reduces the risk of cord infections due to unsanitary birth conditions. Also provided is an identification system which aids in the collection of birth statistics. | 06-03-2010 |
20090324620 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES - The invention features conjugates of therapeutic or cytotoxic agents and biologically active peptides and methods of use thereof. | 12-31-2009 |
20090306311 | METHODS AND INSTRUMENTATION FOR DURING-SYNTHESIS MONITORING OF POLYMER FUNCTIONAL EVOLUTION - A method of monitoring the evolution of polymer and/or colloid stimuli responsiveness during synthesis of polymers and/or colloids, including postpolymerization modifications on natural and synthetic polymers, includes providing a reactor in which the polymers and/or colloids are synthesized; and providing a means of monitoring the stimuli responsiveness of the polymers and/or colloids during said synthesis. Preferably, the method also includes monitoring the evolution of the characteristics of the polymers and/or colloids during said synthesis. Preferably, evolution of polymer and/or colloid stimuli responsiveness is correlated to the evolution of the properties of the polymers and/or colloids themselves. Also, preferably the conditions of the fluid in the reactor in which the synthesis occurs is determined. The determination can be by detection, choice of materials and temperature conditions, for example, and combinations thereof. The method and instrumentation disclosed can lead to optimization and control of processes and synthetic and modification strategies leading to polymers and colloids with desired stimuli responsiveness. | 12-10-2009 |
20090149378 | GLP-1 ANALOGUES - The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. | 06-11-2009 |
20090069245 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders. | 03-12-2009 |
20090047773 | METHOD OF FORMING STABLE FUNCTIONALIZED NANOPARTICLES - A novel top-down procedure for synthesis of stable passivated nanoparticles uses a one-step mechanochemical process to form and passivate the nanoparticles. High-energy ball milling (HEBM) can advantageously be used to mechanically reduce the size of material to nanoparticles. When the reduction of size occurs in a reactive medium, the passivation of the nanoparticles occurs as the nanoparticles are formed. This results in stable passivated silicon nanoparticles. This procedure can be used, for example in the synthesis of stable alkyl- or alkenyl-passivated silicon and germanium nanoparticles. The covalent bonds between the silicon or germanium and the carbon in the reactive medium create very stable nanoparticles. | 02-19-2009 |
20080274543 | Neuronal Cell Propagation Using Rotating Wall Vessel - The present invention provides methods of propagating transformed neurons in a simulated microgravity environment generated by a rotating wall vessel (“3-D culture”) so that the phenotype of the transformed neurons so cultured becomes closer to that of non-transformed neurons (primary neurons) and less like the phenotype of transformed neurons cultured via standard cell culture techniques (“2-D culture”). | 11-06-2008 |